Hutchison China Meditech Ltd buy stratec
Start price
19.02.18
/
50%
€53.06
Target price
19.02.19
€68.27
Performance (%)
-19.57%
End price
19.02.19
€42.67
Summary
This prediction ended on 19.02.19 with a price of €42.67. The price of Hutchison China Meditech Ltd has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -19.57%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Hutchison China Meditech Ltd | -7.910% | -7.910% | 41.739% | -26.244% |
| iShares Core DAX® | 0.192% | 3.121% | 16.828% | 19.649% |
| iShares Nasdaq 100 | 1.245% | 5.051% | 31.022% | 56.928% |
| iShares Nikkei 225® | -0.992% | 1.101% | 9.804% | 6.691% |
| iShares S&P 500 | 0.154% | 2.864% | 26.511% | 47.657% |
Comments by stratec for this prediction
In the thread Hutchison China Meditech Ltd diskutieren
HCM offers investors a strong pipeline of differentiated candidates
The stock offers investors a strong pipeline (up to 15 possible Breakthrough Therapy Designations), China exposur, validating partnerships and several upcoming catalysts. Downside appears limited due to having several irons in the fire, low cash burn as a result of its prescription drug commercial services segment offsetting clinical costs and quite a few pivotal readouts lined up over the next couple years.
stratec stimmt am 19.02.2018 dem Buy-Gesamtsentiment mit dem Kursziel 5990.0p zu.
(Laufzeit überschritten)